Pfizer Jumps At The Chance To Apply Bind’s Technology To Immuno-Oncology
This article was originally published in The Pink Sheet Daily
Executive Summary
Bind has agreed to sell all of its assets to Pfizer for $19.75m after filing for bankruptcy in May. An auction is scheduled for July 25 if other bidders come forward.
You may also be interested in...
Pfizer Buys Anacor With Blockbuster Ambitions For Crisaborole
Pfizer agreed to acquire Anacor for roughly $5.2bn, with the expectation that its late-stage PDE4 inhibitor crisaborole, under review by FDA for the treatment of atopic dermatitis, will generate peak sales of more than $2bn.
Bind Lands Nanoparticle Development Deal With Pfizer
The nanoparticle biotech has signed an agreement with Pfizer to develop an undisclosed number of small molecules that will use the Accurins technology to make the particles easier to use in hard to treat diseases.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.